MR-guided, daily adjusted radiation therapy on a CT-guided radiation device for the precise treatment of ultra-central lung tumors
Résumé de l'étude
You are suffering from a tumor or metastasis that is very close to the central structures within the lung (airway and/or esophagus, main bronchi), also referred to as an 'ultra-central lung tumor.' As a result, it has been recommended to perform a highly precise, so-called 'stereotactic' radiation therapy. In this study, we investigate whether daily adjusted radiation therapy using a special MR simulator and CT-guided radiation is feasible for treating such ultra-central lung tumors and whether it offers advantages over standard, non-daily adjusted radiation therapy. The common type of radiation therapy is CT-based radiation therapy: before the first radiation session, magnetic resonance (MR) or computed tomography (CT) imaging is performed. Based on this imaging, the radiation therapy is planned. All radiation sessions are then conducted according to this plan. A computed tomography scanner is integrated into the radiation device, allowing three-dimensional images to be recorded for patient positioning. In the context of daily adjusted radiation therapy, an imaging (MR imaging) is performed using an MR simulator before each radiation session. The radiation plan is then adjusted according to the imaging. Individual anatomy is subject to daily (usually small) changes, such as a decrease in tumor volume during radiation therapy, the position of the esophagus/airway relative to each other, etc. With daily adjusted radiation therapy, the radiation plan can be immediately adapted to these changes just before each radiation session. This is expected to lead to more precise targeting of the tumor while better sparing surrounding organs compared to solely CT-based radiation therapy.
(BASEC)
Intervention étudiée
Preparation: Before starting radiation, we perform MR imaging in the same position intended for radiation using two special MR simulators with different field strengths (MR simulation). Based on this imaging, we create your baseline radiation plan. It takes about a week to create the baseline radiation plan.
Radiation therapy: On each radiation day, MR simulation is performed again. A new radiation plan is then created based on the latest MR imaging. If this radiation plan meets the quality requirements, you will be treated on the same day with a CT-guided radiation device according to the new radiation plan. If the day's radiation plan does not meet the quality criteria, treatment can still proceed: you will receive therapy according to the original plan created during the first MR simulation, so the radiation series does not have to be interrupted. Once a week, the treatment takes a bit longer because we perform a second MR scan that provides additional information about changes in the tumor and surrounding healthy tissue under radiation.
Follow-up: The follow-up care for study participants after completing radiation therapy corresponds to the current clinical standard and is not altered by the study.
(BASEC)
Maladie en cours d'investigation
Ultra-central lung cancer
(BASEC)
1) 18 years or older 2) Tumor or metastasis that is very close to the central structures within the lung (airway and esophagus, main bronchi), also referred to as an 'ultra-central lung tumor.' 3) Indication for highly precise, so-called 'stereotactic' radiation therapy (based on a recommendation from a multidisciplinary tumor board and/or a clinical practice guideline). (BASEC)
Critères d'exclusion
1) Contraindications for MR (including but not limited to electronic devices such as pacemakers, defibrillators, deep brain stimulators, cochlear implants that are labeled as MR-unsafe, metallic foreign bodies in the eye; severe claustrophobia; hip prostheses that are labeled as MR-unsafe) 2) Previous radiation therapy that directly overlaps with the planned highly precise, so-called 'stereotactic' radiation therapy 3) Pregnant or breastfeeding women, as well as women and men who do not wish to use an effective contraceptive method. (BASEC)
Lieu de l’étude
Zurich
(BASEC)
Sponsor
Universitätsspital Zürich Klinik für Radio-Onkologie
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Dr. med. Lena Kretzschmar
+41 44 255 35 66
Lena.Kretzschmar@clutterusz.chUniversitätsspital Zürich Klinik für Radio-Onkologie
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
11.07.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
MR-informed stereotactic radiotherapy for treatment of ultracentral lung tumours utilising a dedicated MR-simulator for daily adaptation followed by CBCT-guided treatment delivery (MUSIC) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible